State-of-the-art management of nasopharyngeal carcinoma: Current and future directions

M. Agulnik, L. L. Siu*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

53 Scopus citations


Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer. Approximately 70% of patients with newly diagnosed NPC present with locally advanced disease. Phase III clinical trials support the addition of chemotherapy to radiotherapy for the initial treatment of these patients. Once metastatic disease develops, practices become varied. Further experience needs to be gained with both targeted therapies and immunotherapy to gauge whether they will improve treatment outcomes in NPC.

Original languageEnglish (US)
Pages (from-to)799-806
Number of pages8
JournalBritish Journal of Cancer
Issue number5
StatePublished - Mar 14 2005


  • Chemotherapy
  • Immunotherapy
  • Molecular targeted agents
  • Nasopharyngeal carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'State-of-the-art management of nasopharyngeal carcinoma: Current and future directions'. Together they form a unique fingerprint.

Cite this